Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) EVP Linda Burkly sold 4,928 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $2.67, for a total transaction of $13,157.76. Following the completion of the transaction, the executive vice president owned 62,369 shares of the company’s stock, valued at $166,525.23. This trade represents a 7.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Linda Burkly also recently made the following trade(s):
- On Wednesday, June 3rd, Linda Burkly sold 731 shares of Editas Medicine stock. The stock was sold at an average price of $2.70, for a total transaction of $1,973.70.
Editas Medicine Stock Performance
Editas Medicine stock traded down $0.01 during midday trading on Wednesday, reaching $2.61. 1,521,336 shares of the stock were exchanged, compared to its average volume of 2,057,180. Editas Medicine, Inc. has a 52 week low of $1.66 and a 52 week high of $4.54. The firm has a market cap of $255.55 million, a PE ratio of -2.12 and a beta of 2.10. The company’s fifty day moving average is $2.95 and its 200-day moving average is $2.61.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the company. Wall Street Zen lowered Editas Medicine from a “hold” rating to a “sell” rating in a research note on Sunday, May 10th. Chardan Capital lifted their price target on Editas Medicine from $3.50 to $4.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Editas Medicine in a report on Friday, July 17th. Finally, TD Cowen restated a “buy” rating on shares of Editas Medicine in a research report on Wednesday, May 27th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $5.40.
Get Our Latest Stock Report on Editas Medicine
Institutional Investors Weigh In On Editas Medicine
Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its position in shares of Editas Medicine by 138.0% during the 4th quarter. Renaissance Technologies LLC now owns 3,039,778 shares of the company’s stock valued at $6,232,000 after purchasing an additional 1,762,378 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Editas Medicine by 122.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company’s stock valued at $3,016,000 after purchasing an additional 1,430,000 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in shares of Editas Medicine by 761.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 800,023 shares of the company’s stock valued at $2,776,000 after purchasing an additional 707,181 shares during the last quarter. Two Sigma Investments LP grew its holdings in shares of Editas Medicine by 63.3% during the 3rd quarter. Two Sigma Investments LP now owns 1,584,155 shares of the company’s stock valued at $5,497,000 after purchasing an additional 614,229 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in Editas Medicine in the 4th quarter worth $1,166,000. Hedge funds and other institutional investors own 71.90% of the company’s stock.
Editas Medicine Company Profile
Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.
The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.
Read More
- Five stocks we like better than Editas Medicine
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
